Evidence map›Paper›PMID 39853270›Full record

Observational studyBlood advances2025

Cutaneous dysbiosis characterizes the post-allogeneic hematopoietic stem cell transplantation period.

Adela R Cardones, Akintunde Emiola, Russell P Hall, Anthony D Sung, Jennifer Zhang, Amy J Petty, Charles Puza, Lauren M Bohannon, Amy T Bush, Meagan V Lew and 8 more

Abstract readObservational Study
In one paragraph

Observational study in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Adela R CardonesDivision of Dermatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.ORCID 0000-0001-7489-2046
Akintunde EmiolaMicrobial Therapeutics Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD.
Russell P HallDepartment of Dermatology, Duke University Medical Center, Durham, NC.
Anthony D SungDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Jennifer ZhangDepartment of Dermatology, Duke University Medical Center, Durham, NC.ORCID 0000-0002-4485-1750
Amy J PettyDepartment of Dermatology, Duke University Medical Center, Durham, NC.
Charles PuzaDuke University School of Medicine, Durham, NC.
Lauren M BohannonDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Amy T BushDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.ORCID 0000-0002-4495-3765
Meagan V LewDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Elizabeth FlemingMicrobial Therapeutics Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-0588-5066
Yingai J JinDepartment of Dermatology, Duke University Medical Center, Durham, NC.
Krista Rowe NicholsDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.
Vaibhav JainDuke University School of Medicine, Durham, NC.
Simon G GregoryDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC.
Keith M SullivanDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.ORCID 0000-0002-1379-9216
Nelson J ChaoDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC.ORCID 0000-0001-6725-7220
Julia OhDepartment of Dermatology, Duke University Medical Center, Durham, NC.ORCID 0000-0002-5534-7023

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractGut dysbiosis is linked to mortality and the development of graft-versus-host disease after hematopoietic stem cell transplantation (HSCT), but the impact of cutaneous dysbiosis remains unexplored. We performed a pilot observational study, obtained retroauricular and forearm skin swabs from 12 adult patients before conditioning chemotherapy/radiation and at 1 week, 1 month, and 3 months after allogeneic HSCT, and performed shotgun metagenomic sequencing. The cutaneous microbiome among HSCT patients was enriched for gram-negative bacteria such as Escherichia coli and Pseudomonas, fungi, and viruses. Enrichment with bacteriophages and Polyomavirus species was observed among patients who died within 1 year. We observed longitudinal stability of the cutaneous microbiome at the 3-month time point among those who survived beyond 1 year after HSCT, although these may simply be a reflection of the overall medical status of the patients. There was no association with fungal abundance and any of the outcomes observed. The cutaneous microbiome may be a reservoir of pathobionts among allogeneic HSCT patients. Our findings suggest that cutaneous dysbiosis exists after HSCT, but the ultimate implication of this to patient outcomes remains to be seen through larger studies.

Indexed as

DysbiosisHematopoietic Stem Cell TransplantationSkinAdultAgedFemaleGraft vs Host DiseaseHumansMaleMicrobiotaMiddle AgedTransplantation, Homologous

Identifiers

PMID39853270
PMCPMC12243047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.